Relapsed refractory multiple myeloma with CNS involvement successfully treated with Elranatamab: first reported case

Article Oncology

BCMA CAR-T Therapy Is Safe and Effective for Refractory/Relapsed Multiple Myeloma With Central Nervous System Involvement

Yiyun Wang et al.

Summary: This study retrospectively analyzed B-cell maturation antigen CAR-T cell therapy in 4 patients with relapsed/refractory MM involving the CNS. The results showed promising effectiveness and acceptable safety of CAR-T cell therapy for heavily pretreated patients with CNS MM.

JOURNAL OF IMMUNOTHERAPY (2022)

Add to Collection

Meeting Abstract Hematology

Efficacy and Safety of Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma Naive to B-Cell Maturation Antigen (BCMA)-Directed Therapies: Results from Cohort a of the Magnetismm-3 Study

Nizar Jacques Bahlis et al.

BLOOD (2022)

Add to Collection

Review Medicine, General & Internal

Multiple Myeloma with Central Nervous System Relapse Early after Autologous Stem Cell Transplantation: A Case Report and Literature Review

Masaaki Hotta et al.

Summary: Limited reports have discussed the central nervous system involvement in multiple myeloma (MM), which has poor prognosis due to resistance to treatments. This case study presented a 45-year-old female patient who experienced CNS relapse after autologous hematopoietic stem cell transplantation, proposing the potential benefit of immunomodulatory drugs against CNS involvement.

INTERNAL MEDICINE (2021)

Add to Collection

Review Oncology

The Role of Monoclonal Antibodies in the Era of Bi-Specifics Antibodies and CAR T Cell Therapy in Multiple Myeloma

Meera Mohan et al.

Summary: The introduction of monoclonal antibodies in the treatment of multiple myeloma has significantly improved patient outcomes, but the majority of patients will eventually relapse, highlighting the need for novel therapies like bispecific antibodies and chimeric antigen receptor T cells. These emerging treatments show promising results in heavily pretreated and refractory patients, and there is optimism that they may lead to sustained remission and a possible cure in the future.

CANCERS (2021)

Add to Collection

Article Pathology